CO-REFLEX-CES/ENYX
Enyx , a world-class pioneer in ultra-low latency FPGA-based technology and solutions, is pleased to announce its enterprise-class TCP/IP, UDP/IP and MAC network connectivity Intellectual Property (IP) Cores for FPGAs and SoCs support for the high-performance REFLEX CES XpressGXS10-FH200G PCIe Board, which features a Stratix 10 GX FPGA from Intel’s new top-of-the-line 14nm Stratix 10 family
“We are pleased to collaborate with our valued partner REFLEX CES to offer the industry-first TCP and UDP full hardware stacks on Intel’s new, cutting-edge Stratix 10 FPGAs,”says Eric Rovira Ricard, VP Business Development North America at Enyx. “Intel is making FPGA technology ready for data centers, opening new areas for hardware offloading applications in high performance computing, and Enyx is proud to provide the most mature and feature rich network protocol stacks for seamless, FPGA-enabled network connectivity on the latest devices.”
“We are delighted to work with Enyx to offer the best-in-class UDP & TCP IP low latency reference design on our Stratix 10 FPGA board first to market for the Finance and Networking applications, and therefore providing a fast and trusted solution,” said Eric Penain, Chief Business Officer at REFLEX CES.
Enyx nxTCP
and nxUDP
IP Cores feature full RTL Layers 2,3,4 implementations with integrated
40G/25G/10G/1G MAC, compliant with the IEEE
802.3 standards, supporting ARP, IPv4, ICMP, IGMP and TCP/UDP protocols.
nxTCP and nxUDP are designed to work seamlessly on Intel
and Xilinx
FPGA and SoC designs. Enyx TCP implementation on Intel Stratix 10 GX
devices feature latencies of less than 60 ns in transmission and 110 ns
in reception and can also manage up to 32,768 TCP sessions in parallel.
REFLEX
CES XpressGXS10-FH200G
is the first commercially available PCIe
board supporting the 14nm Intel Stratix 10 FPGA family. This board
includes the biggest 2800 KLE Stratix 10 density for processing
intensive and various data algorithms with its mix of memory
capabilities in DDR4 and QDR2+, an optical interface capability of
200Gbit via two QSFP28 cages, uses PCIe gen3 x16. A 200Gbit
board-to-board interface is provided using a firefly connection. REFLEX
CES is an Enyx’ certified board partner.
Starting in 2018, the Intel Stratix 10 version downloadable package will be available and will include a reference design for the REFLEX CES XpressGXS10-FH200G PCIe board.
About Enyx
Enyx is a leading developer and provider of FPGA-based ultra-low latency
technologies and solutions. Enyx Technology & Design Services division
provides design services and connectivity IP cores for FPGA and SoC, for
tailored Smart NICs and Smart Switches.
More information: www.enyx.com
About REFLEX CES
REFLEX CES simplifies the adoption of FPGA technology with its
leading-edge FPGA-based custom embedded and complex systems. REFLEX CES
FPGA network platforms enables better flexibility and ease of
programming, offering a faster and most powerful board, and reducing the
customer's’ technology risks and time to market.
More information: www.reflexces.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20171116005686/en/
Contact:
Enyx
Jacqueline Genow, +16465132924
communication@enyx.com
or
REFLEX
CES
Eric PENAIN, +33(0)169870255
epenain@reflexces.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom